These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30967632)

  • 21. The JAK2 mutation.
    Merchant S
    Int Rev Cell Mol Biol; 2021; 365():117-162. PubMed ID: 34756242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?
    James C
    Hematology Am Soc Hematol Educ Program; 2008; ():69-75. PubMed ID: 19074061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
    Kilpivaara O; Levine RL
    Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.
    Ishii T; Bruno E; Hoffman R; Xu M
    Blood; 2006 Nov; 108(9):3128-34. PubMed ID: 16757685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
    Akada H; Yan D; Zou H; Fiering S; Hutchison RE; Mohi MG
    Blood; 2010 Apr; 115(17):3589-97. PubMed ID: 20197548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.
    Li Z; Xu M; Xing S; Ho WT; Ishii T; Li Q; Fu X; Zhao ZJ
    J Biol Chem; 2007 Feb; 282(6):3428-32. PubMed ID: 17178722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice.
    Chen Y; Shan Y; Lu M; DeSouza N; Guo Z; Hoffman R; Liang A; Li S
    Cancer Res; 2017 Jan; 77(1):164-174. PubMed ID: 27784744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
    Patel AB; Franzini A; Leroy E; Kim SJ; Pomicter AD; Genet L; Xiao M; Yan D; Ahmann JM; Agarwal AM; Clair P; Addada J; Lambert J; Salmon M; Gleich GJ; Cross NCP; Constantinescu SN; O'Hare T; Prchal JT; Deininger MW
    Blood; 2019 Dec; 134(26):2388-2398. PubMed ID: 31697804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
    Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Camacho L; Fernández-Rodríguez MC; Pairet S; Besses C
    Leuk Res; 2016 Sep; 48():11-5. PubMed ID: 27427771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Critical requirement for Stat5 in a mouse model of polycythemia vera.
    Yan D; Hutchison RE; Mohi G
    Blood; 2012 Apr; 119(15):3539-49. PubMed ID: 22144185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.
    Mullally A; Poveromo L; Schneider RK; Al-Shahrour F; Lane SW; Ebert BL
    Blood; 2012 Jul; 120(1):166-72. PubMed ID: 22627765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
    Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
    Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.
    Skov V; Thomassen M; Kjær L; Ellervik C; Larsen MK; Knudsen TA; Kruse TA; Hasselbalch HC
    PLoS One; 2022; 17(6):e0270669. PubMed ID: 35771847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme.
    Roda P; Ferrari A; Tang X; Erlich P; Eisenhower C; Patel MD; Irvin-Barnwell EA
    Ann Hematol; 2014 Sep; 93(9):1467-72. PubMed ID: 24687383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway.
    De Grandis M; Cambot M; Wautier MP; Cassinat B; Chomienne C; Colin Y; Wautier JL; Le Van Kim C; El Nemer W
    Blood; 2013 Jan; 121(4):658-65. PubMed ID: 23160466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation.
    Ahn JS; Li J; Chen E; Kent DG; Park HJ; Green AR
    Oncogene; 2016 Apr; 35(17):2235-46. PubMed ID: 26234675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
    Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
    Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia.
    Wang X; Tripodi J; Kremyanskaya M; Blouin A; Roda P; Hoffman R; Najfeld V
    Blood; 2013 Feb; 121(7):1238-9. PubMed ID: 23411734
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.